Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Delaying treatment of ocular hypertension: the ocular hypertension treatment study.

Kass MA, Gordon MO, Gao F, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish RK, Wilson MR; Ocular Hypertension Treatment Study Group.

Arch Ophthalmol. 2010 Mar;128(3):276-87. doi: 10.1001/archophthalmol.2010.20.

2.

The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO.

Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30.

PMID:
12049574
3.

The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals.

Higginbotham EJ, Gordon MO, Beiser JA, Drake MV, Bennett GR, Wilson MR, Kass MA; Ocular Hypertension Treatment Study Group.

Arch Ophthalmol. 2004 Jun;122(6):813-20.

PMID:
15197055
4.

Asymmetries and visual field summaries as predictors of glaucoma in the ocular hypertension treatment study.

Levine RA, Demirel S, Fan J, Keltner JL, Johnson CA, Kass MA; Ocular Hypertension Treatment Study Group.

Invest Ophthalmol Vis Sci. 2006 Sep;47(9):3896-903.

5.

The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma.

Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Kass MA.

Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30.

PMID:
12049575
6.

The Ocular Hypertension Treatment Study: design and baseline description of the participants.

Gordon MO, Kass MA.

Arch Ophthalmol. 1999 May;117(5):573-83.

PMID:
10326953
7.

The effect of changes in intraocular pressure on the risk of primary open-angle glaucoma in patients with ocular hypertension: an application of latent class analysis.

Gao F, Miller JP, Miglior S, Beiser JA, Torri V, Kass MA, Gordon MO.

BMC Med Res Methodol. 2012 Oct 4;12:151. doi: 10.1186/1471-2288-12-151.

8.

Results of the European Glaucoma Prevention Study.

Miglior S, Zeyen T, Pfeiffer N, Cunha-Vaz J, Torri V, Adamsons I; European Glaucoma Prevention Study (EGPS) Group.

Ophthalmology. 2005 Mar;112(3):366-75.

PMID:
15745761
9.

The utility of the monocular trial: data from the ocular hypertension treatment study.

Bhorade AM, Wilson BS, Gordon MO, Palmberg P, Weinreb RN, Miller E, Chang RT, Kass MA; Ocular Hypertension Treatment Study Group.

Ophthalmology. 2010 Nov;117(11):2047-54. doi: 10.1016/j.ophtha.2010.02.020. Epub 2010 Aug 12.

10.

Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension.

Ocular Hypertension Treatment Study Group; European Glaucoma Prevention Study Group, Gordon MO, Torri V, Miglior S, Beiser JA, Floriani I, Miller JP, Gao F, Adamsons I, Poli D, D'Agostino RB, Kass MA.

Ophthalmology. 2007 Jan;114(1):10-9. Epub 2006 Nov 7.

11.

Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.

Katz G, Dubiner H, Samples J, Vold S, Sall K.

JAMA Ophthalmol. 2013 Jun;131(6):724-30. doi: 10.1001/jamaophthalmol.2013.188.

PMID:
23579344
12.

The incidence of retinal vein occlusion in the ocular hypertension treatment study.

Barnett EM, Fantin A, Wilson BS, Kass MA, Gordon MO; Ocular Hypertension Treatment Study Group.

Ophthalmology. 2010 Mar;117(3):484-8. doi: 10.1016/j.ophtha.2009.08.022. Epub 2010 Jan 19.

13.

The European glaucoma prevention study design and baseline description of the participants.

Miglior S, Zeyen T, Pfeiffer N, Cunha-Vaz J, Torri V, Adamsons I; European Glaucoma Prevention Study Group.

Ophthalmology. 2002 Sep;109(9):1612-21.

PMID:
12208707
14.

Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study.

Budenz DL, Anderson DR, Feuer WJ, Beiser JA, Schiffman J, Parrish RK 2nd, Piltz-Seymour JR, Gordon MO, Kass MA; Ocular Hypertension Treatment Study Group.

Ophthalmology. 2006 Dec;113(12):2137-43. Epub 2006 Sep 25.

15.

Comparison of initial intraocular pressure response with topical beta-adrenergic antagonists and prostaglandin analogues in African American and white individuals in the Ocular Hypertension Treatment Study.

Mansberger SL, Hughes BA, Gordon MO, Spaner SD, Beiser JA, Cioffi GA, Kass MA; Ocular Hypertension Treatment Study Group.

Arch Ophthalmol. 2007 Apr;125(4):454-9.

PMID:
17420364
16.

The accuracy and clinical application of predictive models for primary open-angle glaucoma in ocular hypertensive individuals.

Ocular Hypertension Treatment Study Group and the European Glaucoma Prevention Study Group.

Ophthalmology. 2008 Nov;115(11):2030-6. doi: 10.1016/j.ophtha.2008.06.036. Epub 2008 Sep 18.

17.
18.

Adjusting intraocular pressure for central corneal thickness does not improve prediction models for primary open-angle glaucoma.

Brandt JD, Gordon MO, Gao F, Beiser JA, Miller JP, Kass MA; Ocular Hypertension Treatment Study Group.

Ophthalmology. 2012 Mar;119(3):437-42. doi: 10.1016/j.ophtha.2011.03.018. Epub 2011 Jun 25.

19.

Baseline visual field characteristics in the ocular hypertension treatment study.

Johnson CA, Keltner JL, Cello KE, Edwards M, Kass MA, Gordon MO, Budenz DL, Gaasterland DE, Werner E; Ocular Hypertension Study Group.

Ophthalmology. 2002 Mar;109(3):432-7.

PMID:
11874743
20.
Items per page

Supplemental Content

Write to the Help Desk